Background {#Sec1}
==========

Prevalence of gastric varices in patients with portal hypertension varies from 18 to 70 % \[[@CR1]\]. Bleeding from gastric varices has a mortality rate of 45 % \[[@CR1]\]. There are many treatment options for bleeding gastric varices and, although limited data exist on optimal management, the first-line treatment advocated is endoscopic obliteration using *N*-butyl-2-cyanoacrylate. This liquid glue polymerizes immediately into a plastic cast after contact with blood \[[@CR2], [@CR3]\].

Bacteremia after endoscopic procedures may occur in a frequency of 4.2 %, and can be higher in patients with chronic liver disease and in therapeutic procedures \[[@CR3]\]. Transient bacteremia following injection of cyanoacrylate is not uncommon \[[@CR2]\], but recurrent bacteremia is rarely reported. We aimed to report a case of recurrent bacteremia after *N*-butyl-2-cyanoacrylate treatment and to review the literature for published cases.

Case report {#Sec2}
===========

A 43-year-old Brazilian male was under follow-up at the gastroenterology outpatient clinic due to autoimmune hepatitis-associated liver cirrhosis (Child-Pugh class A/MELD 13). He had portal hypertension and diabetes mellitus and used azathioprine (100 mg/day) and prednisone (10 mg/day). He presented at our emergency department with lower gastrointestinal bleeding in May 2014. Upper endoscopy showed active bleeding from a gastric varix. Hemostasis was achieved by injection of *N*-butyl-2-cyanoacrylate and the patient was discharged 3 days after admission, using propranolol. In July 2014, the patient returned to our hospital with a history of 7 days of fever (up to 40 °C) associated with tachycardia (cardiac rate: 110 beats/min) and hypotension (blood pressure: 80/50 mmHg). There was no headache, nausea, vomiting, diarrhea, abdominal pain, cough, urinary symptoms or bleeding. The patient was admitted to the intensive care unit and ceftriaxone 2 g/day and vasoactive drugs were initiated. Chest radiography and urine exams were normal, and abdomen-CT did not show signs of abscess or ascitis. His blood culture grew *Streptococcus anginosus,* only resistant to clindamycin and erythromycin. The antibiotic was continued for 7 days and the patient quickly improved and was discharged. In August 2014, he returned presenting only fever. His blood culture revealed group C beta-hemolytic *Streptococcus*, only resistant to clindamycin and erythromycin, and *Escherichia coli* susceptible to all antibiotics tested. Full abdomen-CT, chest-CT, transesophageal ecochardiography, colonoscopy and a positron emission tomography did not show any signs of infection. Upper digestive endoscopy did not show any complications at the site of the cyanoacrylate injection. The patient was treated for 4 weeks of IV ceftriaxone and discharged. In September 2014, he returned, presenting with severe sepsis and blood cultures positive for *Enterococcus faecalis* susceptible to ampicillin and *E. coli* susceptible to multiple antibiotics. An abdominal CT was performed and a radio-opaque material was detected within the perigastric and cardiophrenic varicose veins corresponding to cyanoacrylate embolization. Ampicillin (12 g per day) and ceftriaxone were maintained for 4 weeks. Due to the recurrent episodes of bacteremia, the patient was discharged using of amoxicillin--clavulanate (500/125 mg) three times-a-day on a continuous basis. Since then, the patient remains free of episodes of bacteremia.

Literature review {#Sec3}
=================

Besides the present case, six other cases of recurrent bacteremia following variceal sclerosis with *N*-butyl-2-cyanoacrylate were reported in the English language literature. The characteristics of the seven cases are shown in Table [1](#Tab1){ref-type="table"} \[[@CR2], [@CR4], [@CR6], [@CR14]\]. All patients had portal hypertension and the indication of injection of cyanoacrylate was bleeding from gastric varices.Table 1Characteristics of seven patients with recurrent bacteremia following the injection of *N*-butyl-2-cyanoacrylate for the treatment of bleeding gastric varicesCase numberGenderAge (years)Underlying diseasesTime from application of *N*-butyl-2-cyanoacrylate to beginning of symptomsNumber of episodes with positive blood cultureMicroorganism isolated from blood cultureFindings of the investigationTreatmentOutcomeLong term antimicrobial secondary "prophylaxis"Wahl P, 2004 \[[@CR14]\]1Male60Alcoholic liver cirrhosis + portal hypertension3.5 months31st episode: *Propionibacterium acnes* + *Actinomyces odontolyticus*\
2nd episode: *Propionibacterium acnes Streptococcus anginosus* + *Prevotella species*\
3rd episode: *Prevotella oralis*No significant findings1st episode: IV^b^ ceftriaxone (duration not reported)\
2nd episode: amoxicillin/clavulanate (duration not reported)\
3rd episode: moxifloxacin (duration not reported) + surgical debridement of cyanoacrylate plugDeathNo2Male57Alcoholic liver cirrhosis + portal hypertension12 months2*Enterobacter aerogenes*Inflammation around cyanoacrylate plugIV^b^ ceftriaxone (duration not reported)CureYes (oral ciprofloxacin for 3 months)Wright G, 2009 \[[@CR6]\]3Male38Alcoholic liver cirrhosis + portal hypertension6 months3ESBL^a^-producing *E. coli*Cyanoacrylate embolism to inferior vena cava and left renal veinIV^b^ ertapenem for 6 monthsCureNoGalperine T, 2009 \[[@CR4]\]4Male69Idiopathic portal thrombosis + portal hypertension6 months2*Micromonas micros*Abscess contiguous to cyanoacrylate materialIV^b^ clindamycin + impenem for 2 weeksCureYes (oral Cefuroxime for 3 months)5Male46Hepatitis B cirrhosis + portal hypertension + HIV2 weeks3*Klebsiella pneumoniae*Cyanoacrylate embolism to spleen and left renal veinIV^b^ piperacilin/tazobactam for 2 weeksCureYes (oral amoxicillin/clavulanate for 6 weeks and then IV^b^ ceftriaxone for 3 months)Reuken PA, 2012 \[[@CR2]\]6Male77Alcoholic liver cirrhosis + portal hypertension3 months2ESBL^a^-producing *E. coli*Incomplete obliteration of gastric varicesIV^b^ imipenem (duration not reported) + surgery with cardia resection + spleno-renal shuntDeathNoPresent case7Male43Auto immune hepatitis and cirrhosis + portal hypertension + diabetes mellitus2 months31st episode: *Streptococcus anginosus*\
2nd episode: Group C beta-hemolytic *Streptococcus* + *E. coli*\
3rd episode*: E. coli* + *E. faecalis*Cyanoacrilate embolism to perigastric and cardioprhenic veins1st episode: IV^b^ ceftriaxone for 7 days\
2nd episode: IV^b^ ceftriaxone for 4 weeks\
3rd episode: IV^b^ ampicillin + ceftriaxone for 4 weeksCureYes (amoxicillin/clavulanate- indefinitely)^a^ *ESBL* extended spectrum beta-lactamase^b^ *IV* intravenous

The average age of the patients was 55.7 years and the median time from the endoscopic procedure to the first episode of bacteremia was 105 days (range 14--365). The average number of episodes of bacteremia per patient was 2.5.

All cases, after extensive investigation, showed no other focus of infection. In one patient, the same microorganism from the blood culture grew from the cyanoacrylate thrombus after a specimen was collected using endoscopy \[[@CR2]\].

Discussion {#Sec4}
==========

*N*-butyl-2-cyanoacrylate is a liquid glue that can be used in several types of human and veterinary procedures, such as patch fixation for hernia repair \[[@CR7]\], uterine artery embolization for leiomyomas and placenta increta \[[@CR8]\], treatment of renal arteriovenous malformation \[[@CR9]\] and for obliteration of gastric varices \[[@CR1]--[@CR6], [@CR10]--[@CR14]\]. Recurrent bacteremia has been described only for this last procedure.

Around 90 % of patients develop transient fever after *N*-butyl-2-cyanoacrylate injection \[[@CR14]\], however the incidence of bacteremia after the procedure is not clear. Chen et al. observed that the frequency of bacteremia in the cyanoacrylate group was higher than in the group under upper endoscopy without cyanoacrylate injection (15/47 vs. 1/47, *p* \< 0.0001) \[[@CR11]\]. Furthermore, high volume of blood transfusion and Child-Pugh score were factors associated with the occurrence of bacteremia \[[@CR11]\]. Jun et al. observed a frequency of 0.4 % of bacteremia and a Brazilian study did not showed differences in incidence of bacteremia between band ligation and cyanoacrylate injection \[[@CR3]\]. A prospective study with 55 patients only reported bacteremia after injection for treatment of bleeding gastric varices. Elective cyanoacrylate injection for nonbleeding gastric varices was not associated with any episodes of bacteremia \[[@CR13]\].

Recurrent bacteremia, however, is a very rare event with only seven cases described. All patients reported underwent cyanoacrylate treatment for bleeding gastric varices. Because of the rarity of the condition, recurrent bacteremia associated with injection of cyanoacrylate should be a diagnosis of exclusion and other more common diagnoses, such as spontaneous bacterial peritonitis, must be investigated. New diagnostic tools, such as F-18 FDG PET/CT, may be useful in the diagnosis of infected cyanoacrylate plug \[[@CR12]\], but require more studies.

In six of the reported cases including this one, complications associated with cyanoacrylate, such as abscess \[[@CR4]\] or embolism \[[@CR4], [@CR6]\], were found. Two cases of persistent (but not recurrent) bacteremia reported showed incomplete obliteration of gastric varices, possibly facilitating bacterial translocation. In these cases, fever subsided after total obliteration \[[@CR5]\].

Most recurrent episodes of bacteremia were caused by the same microorganism \[[@CR2], [@CR4], [@CR6]\], except for the present report and one other \[[@CR14]\], in which multiple bacteria were implicated. All the microorganisms isolated from blood cultures in all reports were commensals from the oral or gastrointestinal flora. Thus, migration of bacteria from the gastrointestinal lumen to blood vessels was probably facilitated by the cyanoacrylate plug. Polymerization of cyanoacrylate has been described to form a large conglomerate that may protrude intraluminally and provide an ideal route for bacterial invasion \[[@CR10], [@CR14]\].

We believe that after an episode of bacteremia following the injection of *N*-butyl-2-cyanoacrylate for the treatment of bleeding gastric varices, in which there is no evidence of the source of infection, long term secondary prophylaxis with antimicrobials should be considered due to the gravity of these bloodstream infections.

In conclusion, recurrent bacteremia associated with previous endoscopic treatment with *N*-2-butyl-cyanoacrylate is very rare, but should be suspected in patients in which extensive investigation fails to show another focus of infection. Complications associated with cyanoacrylate must be ruled out. Secondary prophylaxis should be considered in these patients after the first episode of bacteremia.

Consent {#Sec5}
=======
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